Exelixis, Inc. and Bristol-Myers Squibb Company Report New Phase 2 Data for XL184 in Patients With the Most Common and Aggressive Form of Brain Cancer

SOUTH SAN FRANCISCO, Calif. & NEW YORK--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today reported updated phase 2 clinical data which show that XL184 demonstrated activity in patients with glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer.